ALLMedicine™ Neurofibromatosis Type 1 Center
Research & Reviews 1,388 results
https://doi.org/10.1148/rg.220062
Radiographics : a Review Publication of the Radiological ... Murphy AN, Kearns C
May 21st, 2022 - Gastrointestinal Stromal Tumors and their Appearance in Patients with Neurofibromatosis Type 1.|2022|Murphy AN,Kearns C,|
https://clinicaltrials.gov/ct2/show/NCT02407405
May 20th, 2022 - Background: Neurofibromatosis 1 (NF1) is an autosomal dominant disorder with an incidence of 1:3500 in the US. One of the cardinal features of NF1 is the development of histologically benign peripheral nervesheath tumors called plexiform neurofibr...
https://clinicaltrials.gov/ct2/show/NCT02423031
May 20th, 2022 - Objective: The purpose of this study is to develop and implement Checking In, a brief and interactive screening measure of distress, designed to identify emotional, physical, social, practical and spiritual concerns of pediatric patients. An accom...
https://clinicaltrials.gov/ct2/show/NCT01702922
May 20th, 2022 - Background: Parents face numerous stressors when their child is diagnosed with cancer or NF1, each of which can strain a marriage/partnership. Marital/partner relationship dynamics are often not assessed or addressed when providing health care for...
https://clinicaltrials.gov/ct2/show/NCT03739827
May 20th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...
Guidelines 4 results
https://doi.org/10.1038/gim.2018.28
Genetics in Medicine : Official Journal of the American C... Stewart DR, Korf BR et. al.
Jul 15th, 2018 - This practice resource is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this practice resource is completely voluntary and does not necessaril...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578356
Neurology Walsh KS, Janusz J et. al.
Aug 17th, 2016 - Neurofibromatosis type 1 (NF1) is associated with neurocognitive deficits that can impact everyday functioning of children, adolescents, and adults with this disease. However, there is little agreement regarding measures to use as cognitive endpoi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578358
Neurology Plotkin SR, Davis SD et. al.
Aug 17th, 2016 - Plexiform neurofibromas (PNs) are complex, benign nerve sheath tumors that occur in approximately 25%-50% of individuals with neurofibromatosis type 1 (NF1). PNs that cause airway compromise or pulmonary dysfunction are uncommon but clinically imp...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578359
Neurology Ahlawat S, Fayad LM et. al.
Aug 17th, 2016 - The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with ne...
Drugs 1 results see all →
Clinicaltrials.gov 35 results
https://clinicaltrials.gov/ct2/show/NCT02407405
May 20th, 2022 - Background: Neurofibromatosis 1 (NF1) is an autosomal dominant disorder with an incidence of 1:3500 in the US. One of the cardinal features of NF1 is the development of histologically benign peripheral nervesheath tumors called plexiform neurofibr...
https://clinicaltrials.gov/ct2/show/NCT02423031
May 20th, 2022 - Objective: The purpose of this study is to develop and implement Checking In, a brief and interactive screening measure of distress, designed to identify emotional, physical, social, practical and spiritual concerns of pediatric patients. An accom...
https://clinicaltrials.gov/ct2/show/NCT01702922
May 20th, 2022 - Background: Parents face numerous stressors when their child is diagnosed with cancer or NF1, each of which can strain a marriage/partnership. Marital/partner relationship dynamics are often not assessed or addressed when providing health care for...
https://clinicaltrials.gov/ct2/show/NCT03739827
May 20th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...
https://clinicaltrials.gov/ct2/show/NCT03531814
May 20th, 2022 - Background: Neurofibromatosis type 1 (NF1) is a genetic disorder that affects approximately 1 in 3,500 individuals and is associated with a broad variety of symptoms and physical findings. Plexiform neurofibromas (PN) are histologically benign tum...
News 34 results
https://www.onclive.com/view/dr-trent-on-the-utility-of-ctdna-to-understand-primary-mutations-in-gist
Oct 6th, 2021 - Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the utility of circulating tumor DNA (ctDNA) to understand primary driver...
https://www.medscape.com/viewarticle/958224
Sep 6th, 2021 - A novel liquid biopsy test has been shown to distinguish between patients with neurofibromatosis type 1 (NF1) who have benign plexiform neurofibroma (PN) precursor lesions from patients who have malignant peripheral nerve sheath tumors (MPNST), sa...
https://www.mdedge.com/dermatology/article/243441/pediatrics/genetic-testing-neurofibromatosis-1-imperfect-science
Doug Brunk
Jul 27th, 2021 - When a child presents with café au lait macules, when is genetic testing for neurofibromatosis type 1 (NF1) advised? According to Peter Kannu, MB, ChB, DCH, PhD, a definitive diagnosis of NF1 can be made in most children using National Institutes.
https://www.medscape.com/viewarticle/955499
Jul 27th, 2021 - When a child presents with café au lait macules, when is genetic testing for neurofibromatosis type 1 (NF1) advised? According to Peter Kannu, MB, ChB, DCH, PhD, a definitive diagnosis of NF1 can be made in most children using National Institutes ...
https://www.onclive.com/view/selumetinib-approved-in-europe-for-pediatric-neurofibromatosis-type-1-and-plexiform-neurofibromas
Jun 22nd, 2021 - The European Commission has granted a conditional approval to selumetinib (Koselugo) for the treatment of pediatric patients with symptomatic, inoperable plexiform neurofibromas (PN) and neurofibromatosis type 1 (NF1) who are at least 3 years of a...